The ADSs are approved to list on Nasdaq under AAPG, with J.P. Morgan and Citigroup as the underwriters named on the cover. The company's ordinary shares have traded in Hong Kong under code 6855 since October 28, 2019.
The Cayman Islands company's shares have traded in Hong Kong under stock code 6855 since October 28, 2019. The ADS count and price are blank, and J.P. Morgan and Citigroup are named on the cover.
Ascentage Pharma Group International annual financials
Latest balance sheet, Dec 31, 2024 (20-F): cash and equivalents $122.4 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Ascentage Pharma Group International
When did Ascentage Pharma Group International go public?
Our latest story on this, dated Jan 24, 2025: "Ascentage Pharma prices U.S. IPO of 7,325,000 ADSs at US$17.25". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Ascentage Pharma Group International?
Ascentage Pharma Group International trades under the ticker 6855 on HKEX.
Where is Ascentage Pharma Group International listed?
Ascentage Pharma Group International is listed on HKEX. Our directory also records these other listings: NASDAQ:AAPG; OTC:ASPHF.
What is the SEC CIK of Ascentage Pharma Group International?
The SEC Central Index Key (CIK) for Ascentage Pharma Group International is 2023311. Its filings are on SEC EDGAR.
How many shares does Ascentage Pharma Group International have outstanding?
373,322,192 shares as of 2026-04-01, per the cover page of its 20-F filed 2026-04-29.
Which country or territory is Ascentage Pharma Group International listed under?
Our directory records Ascentage Pharma Group International under China.
What does Ascentage Pharma Group International do?
Our directory classifies Ascentage Pharma Group International as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Ascentage Pharma Group International?
The ISIN recorded for Ascentage Pharma Group International is KYG0519B1023.
Does aibio.space cover Ascentage Pharma Group International?
aibio.space lists Ascentage Pharma Group International among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Ascentage Pharma Group International incorporated?
SEC records list its state or country of incorporation as E9.
What was Ascentage Pharma Group International's revenue last year?
$134.3 million for the fiscal year ended Dec 31, 2024, as reported to the SEC.
Is Ascentage Pharma Group International profitable?
Ascentage Pharma Group International reported a net loss of $55.6 million for the fiscal year ended Dec 31, 2024, and used $15.3 million of cash in operations, per its annual report to the SEC.
How much does Ascentage Pharma Group International spend on research and development?
$129.8 million in the fiscal year ended Dec 31, 2024, per its annual report.
How much cash does Ascentage Pharma Group International have?
$122.4 million in cash at Dec 31, 2024, per its 20-F.
What is the latest Ascentage Pharma Group International (6855) stock news?
Our latest story on Ascentage Pharma Group International, dated Jan 24, 2025: "Ascentage Pharma prices U.S. IPO of 7,325,000 ADSs at US$17.25". The ADSs are approved to list on Nasdaq under AAPG, with J.P. Morgan and Citigroup as the underwriters named on the cover. The company's ordinary shares have traded in Hong Kong under code 6855 since October 28, 2019. Source.
Investor discussion: Ascentage Pharma Group International
Members talk about Ascentage Pharma Group International (6855). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Ascentage Pharma Group International, newest first. Each line links the filing it comes from.
Share or debt issue: PROPOSED RE-ELECTION OF RETIRING DIRECTORS;
PROPOSED GRANTING OF GENERAL MANDATES
TO ISSUE SHARES AND REPURCHASE SHARES;
PROPOSED AMENDMENTS TO THE MEMORANDUM AND
ARTICLES OF ASSOCIATION AND PROPOSED ADOPTION OF
THE THIRD AMENDED AND RESTATED MEMORANDUM AND
ARTICLES OF ASSOCIATION; AND
NOTICE OF ANNUAL GENERAL MEETING. Source
Financings
Share or debt issue: CLOSING OF PLACING OF EXISTING SHARES
AND
TOP-UP SUBSCRIPTION OF NEW SHARES UNDER
GENERAL MANDATE. Source
Share or debt issue: PROPOSED RE-ELECTION OF RETIRING DIRECTORS,
PROPOSED GRANTING OF GENERAL MANDATES
TO ISSUE SHARES AND REPURCHASE SHARES
AND
NOTICE OF ANNUAL GENERAL MEETING. Source
Financings
Share or debt issue: CLOSING OF THE PARTIAL EXERCISE OF THE
OVER-ALLOTMENT OPTION
IN RELATION TO
THE OFFERING OF AMERICAN DEPOSITARY SHARES. Source
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:6855 on TradingView.
SEC filings and registration
SEC name
Ascentage Pharma Group International
CIK
2023311
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
AAPG (Nasdaq)
State or country of incorporation
E9
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Emerging growth company
Business address
68 XINQING ROAD, SUZHOU , JIANGSU
Phone
86 512 8555 7777
Shares outstanding
373,322,192 as of 2026-04-01 (20-F filed 2026-04-29)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Ascentage Pharma Group International is a public biotech or pharmaceutical company listed on HKEX under the ticker 6855, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio